Free Access
Med Sci (Paris)
Volume 27, Number 5, Mai 2011
Page(s) 501 - 507
Section M/S Revues
Published online 25 May 2011
  1. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989 ; 264 : 4743-4746. [PubMed] [Google Scholar]
  2. Gandrille S, Saposnik B, Aiach M. Le récepteur endothélial à la protéine C (EPCR) : un récepteur à l’interface entre coagulation et système inflammatoire. Hématologie 2001 ; 7 : 418-28. [Google Scholar]
  3. Esmon CT, Fukudome K. Cellular regulation of the protein C pathway. Semin Cell Biol 1995 ; 6 : 259-268. [CrossRef] [PubMed] [Google Scholar]
  4. Dahlback B. Protein S and C4b-binding protein : components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991 ; 66 : 49-61. [PubMed] [Google Scholar]
  5. Aiach M, Alhenc-Gelas M, Borgel D, et al. Mutations des protéines de la coagulation et thromboses. Med Sci (Paris) 2006 ; 22 : 985-989. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001 ; 276 : 15567-15570. [CrossRef] [PubMed] [Google Scholar]
  7. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units : results of the SOAP study. Crit Care Med 2006 ; 34 : 344-353. [CrossRef] [PubMed] [Google Scholar]
  8. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001 ; 13 : 85-94. [CrossRef] [PubMed] [Google Scholar]
  9. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001 ; 29 : S90-S94. [CrossRef] [PubMed] [Google Scholar]
  10. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 2010 ; 38 : S35-S42. [CrossRef] [PubMed] [Google Scholar]
  11. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005 ; 15 : 254-259. [CrossRef] [PubMed] [Google Scholar]
  12. van der Poll T, Levi M, Hack CE, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994 ; 179 : 1253-1259. [CrossRef] [PubMed] [Google Scholar]
  13. Jansen PM, Boermeester MA, Fischer E, et al. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis : studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood 1995 ; 86 : 1027-1034 [PubMed] [Google Scholar]
  14. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991 ; 88 : 1346-1353. [CrossRef] [PubMed] [Google Scholar]
  15. Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003 ; 1 : 1343-1348. [CrossRef] [PubMed] [Google Scholar]
  16. McLaughlin JN, Shen L, Holinstat M, et al. Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J Biol Chem 2005 ; 280 : 25048-25059. [CrossRef] [PubMed] [Google Scholar]
  17. Joyce DE, Nelson DR, Grinnell BW. Leukocyte and endothelial cell interactions in sepsis : relevance of the protein C pathway. Crit Care Med 2004 ; 32 : S280-S286. [CrossRef] [PubMed] [Google Scholar]
  18. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005 ; 105 : 3178-3184. [CrossRef] [PubMed] [Google Scholar]
  19. Sturn DH, Kaneider NC, Feistritzer C, et al. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003 ; 102 : 1499-1505. [CrossRef] [PubMed] [Google Scholar]
  20. Elphick GF, Sarangi PP, Hyun YM, et al. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 2009 ; 113 : 4078-4085. [CrossRef] [PubMed] [Google Scholar]
  21. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002 ; 296 : 1880-1882. [CrossRef] [PubMed] [Google Scholar]
  22. Cao C, Gao Y, Li Y, et al. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest 2010 ; 120 : 1971-1980. [CrossRef] [PubMed] [Google Scholar]
  23. Mahidhara R, Billiar TR. Apoptosis in sepsis. Crit Care Med 2000 ; 28 : N105-N113. [CrossRef] [PubMed] [Google Scholar]
  24. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003 ; 101 : 3765-3777. [CrossRef] [PubMed] [Google Scholar]
  25. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003 ; 9 : 338-342. [CrossRef] [PubMed] [Google Scholar]
  26. Stephenson DA, Toltl LJ, Beaudin S, Liaw PC. Modulation of monocyte function by activated protein C, a natural anticoagulant. J Immunol 2006 ; 177 : 2115-2122. [PubMed] [Google Scholar]
  27. Conway EM, Van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002 ; 196 : 565-577. [CrossRef] [PubMed] [Google Scholar]
  28. Anderson HA, Maylock CA, Williams JA, et al. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 2003 ; 4 : 87-91. [CrossRef] [PubMed] [Google Scholar]
  29. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009 ; 15 : 1318-1321. [CrossRef] [PubMed] [Google Scholar]
  30. Viatte L Dr Jekyll et Mr Histone : protéger ou tuer, la dualité des histones. Med Sci (Paris) 2010 ; 26 : 144. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  31. Shorr AF, Bernard GR, Dhainaut JF, et al. C Protein concentrations in severe sepsis : an early directional change in plasma levels predicts outcome. Crit Care 2006 ; 10 : R92. [CrossRef] [PubMed] [Google Scholar]
  32. Taylor FB, Jr., Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987 ; 79 : 918-925. [CrossRef] [PubMed] [Google Scholar]
  33. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007 ; 204 : 2439-2448. [CrossRef] [PubMed] [Google Scholar]
  34. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 ; 344 : 699-709. [CrossRef] [PubMed] [Google Scholar]
  35. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003 ; 31 : 12-19. [CrossRef] [PubMed] [Google Scholar]
  36. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : further evidence for survival and safety and implications for early treatment. Crit Care Med 2005 ; 33 : 2266-2277. [CrossRef] [PubMed] [Google Scholar]
  37. Payen D, Sundin DP, Nelson DR, Williams MD. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database. Surgery 2007 ; 142 : 426-427. [CrossRef] [Google Scholar]
  38. Thompson BT, Ranieri VM, Finfer S, et al. Statistical analysis plan of PROWESS SHOCK study. Intensive Care Med 2010 ; 36 : 1972-1973. [CrossRef] [PubMed] [Google Scholar]
  39. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005 ; 353 : 1332-1341. [CrossRef] [PubMed] [Google Scholar]
  40. Carlet J. Prescribing indications based on successful clinical trials in sepsis : a difficult exercise. Crit Care Med 2006 ; 34 : 525-529. [CrossRef] [PubMed] [Google Scholar]
  41. Vieillard-Baron A, Caille V, Charron C, et al. Reversal of refractory septic shock with drotrecogin alpha (activated). Intensive Care Med 2009 ; 35 : 1204-1209. [CrossRef] [PubMed] [Google Scholar]
  42. Dumont B, Faille D, Ajzenberg N. Les nouveaux anticoagulants oraux : dabigatran, rivaroxaban et apixaban. Leur utilisation actuelle et leur avenir. Med Sci (Paris) 2011 ; 27 : 493-500. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.